

Risk of bias assessment according to the methodological index for non-randomized studies (MINORS) per outcome:

Disease control rate (DCR) according to RECIST 1.1 at 3 months follow-up:

		Risk of bias								
		D1	D2	D3	D4	D5	D6	D7	D8	Overall
Study	Smits 2012	+	✗	+	+	+	+	-	✗	-
	Roosen 2022	+	✗	+	+	✗	+	+	✗	-
	Prince 2018	+	✗	+	+	+	+	+	+	+
	Ramdhani 2024	+	-	-	+	✗	+	-	✗	-
	Wagemans 2018	+	✗	+	+	✗	+	-	✗	-
	Braat 2020	+	✗	+	+	+	-	+	+	+

D1: A clearly stated aim
 D2: Inclusion of consecutive patients
 D3: Prospective collection of data
 D4: Endpoints appropriate to the aim of the study
 D5: Unbiased assessment of the study endpoint
 D6: Follow-up period appropriate to the aim of the study
 D7: Loss to follow up less than 5%
 D8: Prospective calculation of the study type

Judgement
 X High
 - Moderate
 + Low

DCR according to mRECIST at 3 months follow-up:

		Risk of bias								
		D1	D2	D3	D4	D5	D6	D7	D8	Overall
Study	Drescher 2023									
	Radosa 2019									
	Dökdök 2023									
	Reinders 2022									
	Braat 2020									

D1: A clearly stated aim

D2: Inclusion of consecutive patients

D3: Prospective collection of data

D4: Endpoints appropriate to the aim of the study

D5: Unbiased assessment of the study endpoint

D6: Follow-up period appropriate to the aim of the study

D7: Loss to follow up less than 5%

D8: Prospective calculation of the study type

Judgement

 High

 Moderate

 Low

Overall survival (OS):

		Risk of bias								
		D1	D2	D3	D4	D5	D6	D7	D8	Overall
Study	Drescher 2023									
	Reinders 2022									
	Prince 2018									
	Ebbers 2022									
	Hendriks 2024									
	Ramdhani 2024									
	Roekel 2021									
D1: A clearly stated aim D2: Inclusion of consecutive patients D3: Prospective collection of data D4: Endpoints appropriate to the aim of the study D5: Unbiased assessment of the study endpoint D6: Follow-up period appropriate to the aim of the study D7: Loss to follow up less than 5% D8: Prospective calculation of the study type Judgement High Moderate Low										

Progression-free survival (PFS):

		Risk of bias								
		D1	D2	D3	D4	D5	D6	D7	D8	Overall
Study	Prince 2018									
	Ramdhani 2024									
	Ebbers 2022									
	Hendriks 2024									

- D1: A clearly stated aim
- D2: Inclusion of consecutive patients
- D3: Prospective collection of data
- D4: Endpoints appropriate to the aim of the study
- D5: Unbiased assessment of the study endpoint
- D6: Follow-up period appropriate to the aim of the study
- D7: Loss to follow up less than 5%
- D8: Prospective calculation of the study type

Judgement

- High
- Moderate
- Low

Clinical adverse events according to CTCAE:

		Risk of bias								
		D1	D2	D3	D4	D5	D6	D7	D8	Overall
Study	Ramdhani 2024	+	-	-	+	X	+	-	X	-
	Reinders 2022	+	X	+	+	+	+	+	+	+
	Drescher 2023	+	X	+	+	X	+	+	X	-
	Radosa 2019	+	X	+	+	X	+	+	X	-
	Dökdök 2023	+	-	+	+	X	+	-	X	-
	Roosen 2022	+	X	+	+	X	+	+	X	-
	Smits 2012	+	X	+	+	+	+	+	X	-
	Prince 2018	+	X	+	+	+	+	+	-	+
	Braat 2020	+	X	+	+	+	+	+	-	+
	Hendriks 2024	+	X	+	+	X	+	-	-	-

D1: A clearly stated aim
 D2: Inclusion of consecutive patients
 D3: Prospective collection of data
 D4: Endpoints appropriate to the aim of the study
 D5: Unbiased assessment of the study endpoint
 D6: Follow-up period appropriate to the aim of the study
 D7: Loss to follow up less than 5%
 D8: Prospective calculation of the study type

Judgement
 X High
 - Moderate
 + Low

Laboratory adverse events according to CTCAE:

		Risk of bias								
		D1	D2	D3	D4	D5	D6	D7	D8	Overall
Study	Ramdhani 2024	+	-	-	+	X	+	-	X	-
	Prince 2018	+	X	+	+	+	+	+	-	+
	Braat 2020	+	X	+	+	+	+	+	-	+
	Dökdök 2023	+	-	+	+	X	+	-	X	-
	Radosa 2019	+	X	+	+	X	+	+	X	-
	Reinders 2022	+	X	+	+	+	+	+	+	+
	Smits 2012	+	X	+	+	+	+	+	X	-
		D1: A clearly stated aim D2: Inclusion of consecutive patients D3: Prospective collection of data D4: Endpoints appropriate to the aim of the study D5: Unbiased assessment of the study endpoint D6: Follow-up period appropriate to the aim of the study D7: Loss to follow u less than 5% D8: Prospective calculation of the study type								Judgement X High - Moderate + Low

Tumor absorbed dose:

		Risk of bias								
		D1	D2	D3	D4	D5	D6	D7	D8	Overall
Study	Smits 2013	+	X	+	+	X	+	+	X	-
	Wagemans 2018	+	X	+	+	X	+	-	X	-
	Reinders 2022	+	X	+	+	-	+	+	-	-
	Ramdhani 2024	+	-	-	+	X	+	-	X	-
	Roosen 2022	+	X	+	+	+	+	+	X	-
	Radosa 2019	+	X	+	+	X	+	-	X	-
	Hendriks 2024	+	X	+	+	X	+	+	+	-
	Dökdök 2023	+	-	+	+	X	+	-	X	-
	Bastiaannet 2019	+	X	+	+	X	+	+	X	-
		D1: A clearly stated aim D2: Inclusion of consecutive patients D3: Prospective collection of data D4: Endpoints appropriate to the aim of the study D5: Unbiased assessment of the study endpoint D6: Follow-up period appropriate to the aim of the study D7: Loss to follow up less than 5% D8: Prospective calculation of the study type								Judgement X High - Moderate + Low

Healthy liver absorbed dose:

		Risk of bias								
		D1	D2	D3	D4	D5	D6	D7	D8	Overall
Study	Stella 2023									
	Smits 2013									
	Wagemans 2018									
	Bastiaannet 2019									
	Hendriks 2024									
		D1: A clearly stated aim D2: Inclusion of consecutive patients D3: Prospective collection of data D4: Endpoints appropriate to the aim of the study D5: Unbiased assessment of the study endpoint D6: Follow-up period appropriate to the aim of the study D7: Loss to follow up less than 5% D8: Prospective calculation of the study type								Judgement High Moderate Low